Innate Pharma Updates Share and Voting Rights as of April 2026

Innate Pharma, a biotechnology company based in Marseille, France, has disclosed its total number of shares and voting rights as of April 9, 2026. According to the release, the company has 93,860,680 shares outstanding, which includes 93,847,763 ordinary shares, 5,336 Preferred Shares 2016, and 7,581 Preferred Shares 2017.

The total number of theoretical voting rights stands at 94,484,443, while the exercisable voting rights are 94,465,868. The theoretical voting rights count all shares with voting potential, including those with suspended rights, to calculate shareholding thresholds.

The company, dual-listed on Euronext Paris and Nasdaq, focuses on developing antibody therapeutics for cancer treatment. It maintains collaborations with major biopharmaceutical firms and aims to address unmet medical needs through its innovative portfolio.